M ultimorbidity, although difficult to define, 1 typically refers to the presence of two or more chronic conditions 2 ; 70% of adults aged 75 and older experience multimorbidity. 3 Nearly 55% of Medicare beneficiaries with stroke and heart failure have five or more additional chronic conditions. 4 Increases in the prevalence of multimorbidity are anticipated because of rapid growth in the aging population, medical advances, and greater longevity. 3, 5 Multimorbidity is negatively associated with health status and quality of life 6 and is related to greater healthcare use, costs, 7, 8 and mortality. 5, 9 Interventions targeting the assessment, treatment, and symptom management of individuals with multimorbidity 10, 11 are lacking, especially for those with advanced, life-limiting illness. In addition, multimorbidity is often excluded from disease-specific research. 12 Although there are some data describing the effect of multimorbidity on health outcomes, little is known about the effect of multimorbidity in the setting of life-limiting illness. 13, 14 This analysis investigated the relationship between multimorbidity, symptom burden, and functional status in individuals with life-limiting illness. Better understanding the relationship between symptom burden, functional status, and multimorbidity could inform improvements in care for older adults with life-limiting illness. We sought to understand the relationship between multimorbidity and symptom burden, controlling for functional status, primary diagnosis of cancer, age, and sex, the relationship between multimorbidity and functional status, controlling for symptom burden, primary diagnosis of cancer, age, and sex.
METHODS
This was a secondary analysis of baseline data from a multisite randomized clinical trial of statin discontinuation conducted in the Palliative Care Research Cooperative Group. The results of the parent trial are published elsewhere. 15 All participants of the parent trial were included in the analysis. Eligibility criteria included having been taking a statin for 3 months or longer for primary or secondary prevention, a progressive life-limiting illness as determined by the treating physician stating that he or she would not be surprised if the individual died in the next year, life expectancy longer than 1 month also determined by the treating physician, and declining functional status defined as a reduction in Australia-modified Karnofsky Performance Status (AKPS) score to less than 80% in the previous 3 months. Cancer diagnosis was defined as a primary diagnosis of solid organ or hematological malignancy. Multimorbidity was defined as a Charlson Comorbidity Index (CCI) score greater than 2; the CCI weights a combination of chronic conditions documented from the medical record based on a scale of 1 to 6, with higher scores indicating greater multimorbidity. 16 Symptom burden was measured using the Edmonton Symptom Assessment Scale (ESAS), which captures ratings of symptom severity for nine symptoms (pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, shortness of breath, well-being) on scale from 0 to 10, for a total score of 0 to 90, with higher scores indicating greater symptom burden. 17 An individual symptom score greater than 4 was considered to be moderate, and greater than 7 was considered to be severe. Moderate symptom burden was defined as the number of symptoms with a severity score greater than 4, symptom severity was defined as the proportion of symptoms with a severity score greater than 7. Functional status, reported by the individual, was measured using the Australia-modified Karnofsky Performance Scale (AKPS), with scores ranging from 100 (normal, no complaints, no evidence of disease) to 0 (dead). 18 Group differences were tested using the ttest; multivariate regression analysis was used to determine the effect of multiple variables on functional status and on symptom burden ( Figure S1 ).
RESULTS
Participants (N = 381) had multiple comorbid illnesses, numerous symptoms, and consistent with study entry eligibility criteria, poor functional status ( Table 1 ). The mostcommon noncancer comorbid illnesses were chronic obstructive pulmonary disease (32%), congestive heart failure (26%), and cardiovascular disease (22%).
Univariate results are summarized in Table 2 . Multimorbidity was associated with number of symptoms with an ESAS score greater than 4 (P = .002) and proportion with severe symptoms (ESAS score >7) (P < .001) but not with functional status. Participants with a primary diagnosis that was not cancer had worse functional status (AKPS score 48.5 AE 12.9) than those with a primary diagnosis of cancer (AKPS score 58.1 AE 11.4) (P < .001). There were no univariate associations between primary diagnosis of cancer and symptom burden.
Multivariate analyses (Table 3) showed that multimorbidity was associated with greater symptom burden (t = 2.44, P = .02) but not with functional status. Cancer diagnosis was not independently associated with symptom burden, whereas poor functional status was associated with greater symptom burden (t = À3.40, P = .001). Noncancer primary diagnosis (t = 4.03, P < .001) and greater symptom burden (t = À3.40, P = .001) were associated with worse functional status.
DISCUSSION
Multimorbidity was associated with symptom burden but not with functional status. A cancer diagnosis was associated with better functional status, and greater symptom burden was associated with worse functional status. Participants with multimorbidity had higher symptom burden, and those with a noncancer primary diagnosis and with greater symptom burden had poorer functional status. Although multimorbidity was associated with higher symptom burden, cancer was not. Severe and persistent symptoms have previously been linked to multimorbidity in community-dwelling older adults, 19, 20 and greater symptom burden has been associated with multimorbidity in individuals with cancer. 21, 22 These findings, in concert with those of previous studies, suggest that, in many instances, noncancer diagnoses drive symptom burden whether the individual has cancer or not. In contrast to previous research indicating an association between multimorbidity, impairments in function, 23 and health-related quality of life, 24 our data did not show a relationship between multimorbidity and functional status, controlling for symptom burden, although multimorbidity has been associated with symptoms that are directly related to restrictions in activities of daily living, particularly in the last 5 months of life. 25 Therefore, symptoms may be the pathway by which multimorbidity influences functional status.
Symptom burden, rather than multimorbidity, was associated with poorer functional status. Previous studies highlighting the relationship between symptom severity, quality of life, and functional status corroborate this result. [26] [27] [28] Symptom burden may be a mediating variable between multimorbidity and functional status, although it is also possible that specific symptoms, such as depression and fatigue, drive this relationship, rather than overall moderate to severe symptom burden. For example, depression and fatigue have previously been shown to exacerbate symptom burden and functional limitations in individuals with life-limiting illness. [29] [30] [31] Therefore, our results may be detecting the relationship between depression, fatigue, and functional status. The potential association between specific symptoms, symptom burden, and functional status underscores the importance of focusing on symptom burden rather than simply diagnosis in individuals with multimorbidity.
Although cancer was not independently related to symptom burden, individuals with a primary diagnosis of cancer had better function than those with a noncancer diagnosis. Our findings suggest that symptoms that individuals with life-limiting illnesses experience cannot be attributed solely to a diagnosis of cancer. Previous studies suggest that individuals with life-limiting illness have high symptom burden, particularly pain, regardless of diagnosis. 32 Multimorbidity is also common in individuals with cancer, and clinicians have difficultly addressing these individuals' symptoms. 22 Providers of cancer care may not consider that symptoms might be emanating from conditions other than cancer. As such, individuals with cancer with multimorbidity have been found to take more medications, experience greater illness burden, and be at greater risk of undertreatment. 33 Given the association between multimorbidity and symptom burden and the relationship between symptom burden and functional status, these findings suggest that careful clinical attention should be paid to symptoms, regardless of diagnosis, particularly in the setting of multimorbidity, although symptom management is more complex in the context of multimorbidity because of limitations in pharmacological options, multiprovider coordination, difficulty applying standardized guidelines, and complicated self-care regimens. 34, 35 Our findings support the growing evidence recommending a shift from disease-specific treatment to addressing symptoms in the context of multimorbidity. Nonpharmacological behavioral treatments with the potential to improve more than one kind of symptom may be particularly valuable in the context of multimorbidity. 36 There are limitations to this analysis. This was a secondary analysis of data collected from a clinical trial. Because participants agreed to participate in the trial and were all using statins at the time of study entry, the findings may not represent the diagnosis distribution, symptom burden, or functional status of all older adults with lifelimiting illness. Although our models were adjusted for age, sex, symptom burden, and functional status, it is likely that we were unable to control for every confounding variable in the tested relationships. There was also a difference in survival according to diagnosis; individuals with a noncancer primary diagnosis lived longer than those with cancer. Multimorbidity was assessed as presence or absence of multiple comorbid conditions but not severity of the conditions. An indicator of illness severity in addition to multimorbidity might have demonstrated a stronger relationship between multimorbidity and function. Inclusions of diagnosis not specified in the CCI may also have strengthened our measurement of multimorbidity. In addition, the AKPS may not have fully capture functional status. The AKPS only considers generic assistance and is In conclusion, our data suggest that multimorbidity is associated with symptom burden. Our work also suggests that symptom burden is associated with functional status. Future research should focus on better understanding the relationship between symptom burden and multimorbidity. Better measures that include diagnosis and illness severity to capture multimorbidity and effective approaches to address symptom burden in older adults with life-limiting illness and multimorbidity are needed. Conflict of Interest: The authors have no financial or personal conflicts to disclose.
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